138849-26-0
Chemical Structure
Thrombospondin (TSP-1)-derived CD36 binding motif
- CAS No.: 138849-26-0
- Formula:C20H34N6O9S2
- Molecular Weight:566.65
InChIKey: BKKZTICNTWDYCN-YLHZTVIJSA-N
SMILES: O=C([C@@H](N)CSSC[C@H](NC1=O)C(NCC(O)=O)=O)N[C@H](C(N[C@H](C(N[C@H]1[C@@H](C)O)=O)C(C)C)=O)CO
Biological Activity: Thrombospondin (TSP-1)-derived CD36 binding motif is a bioactive hexapeptide. Thrombospondin (TSP-1)-derived CD36 binding motif interferes with the interaction between cells and the extracellular matrix by binding to CD36 and angiostatin, thereby affecting the cell adhesion and migration process. Thrombospondin (TSP-1)-derived CD36 binding motif inhibits platelet aggregation. Thrombospondin (TSP-1)-derived CD36 binding motif exerts an anti-tumor effect against colon cancer[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Thrombospondin (TSP-1)-derived CD36 binding motif | 99.58% | Thrombospondin (TSP-1)-derived CD36 binding motif is a bioactive hexapeptide. Thrombospondin (TSP-1)-derived CD36 binding motif interferes with the interaction between cells and the extracellular matrix by binding to CD36 and angiostatin, thereby affecting the cell adhesion and migration process. Thrombospondin (TSP-1)-derived CD36 binding motif inhibits platelet aggregation. Thrombospondin (TSP-1)-derived CD36 binding motif exerts an anti-tumor effect against colon cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Asch AS, et al. Thrombospondin sequence motif (CSVTCG) is responsible for CD36 binding. Biochem Biophys Res Commun. 1992 Feb 14;182(3):1208-17. [Content Brief]
- [2]. Pijuan-Thompson V, et al. Retinoic acid alters the mechanism of attachment of malignant astrocytoma and neuroblastoma cells to thrombospondin-1. Exp Cell Res. 1999 May 25;249(1):86-101. [Content Brief]
- [3]. Tsao PW, et al. Thrombospondin mediates calcium mobilization in fibroblasts via its Arg-Gly-Asp and carboxyl-terminal domains. J Biol Chem. 1995 Oct 6;270(40):23747-53. [Content Brief]
- [4]. Liebig C, et al. Angiocidin inhibitory peptides decrease tumor burden in a murine colon cancer model. J Surg Res. 2007 Oct;142(2):320-6. [Content Brief]
